- Baxter International's (NYSE:BAX) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder.
- BAX 111 successfully treated 22 patients who experienced bleeding episodes during the trial.
- Secondary endpoints included those related to additional efficacy and safety measures, pharmacokinetics and health-related quality of life.
- Shares are +1.55% premarket. (PR)
Baxter's BAX 111 treats 100% of bleeding episodes in small Phase III
Recommended For You
More Trending News
About BAX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BAX | - | - |
Baxter International Inc. |